Home/Filings/4/0001209191-16-096375
4//SEC Filing

Conatus Pharmaceuticals Inc. 4

Accession 0001209191-16-096375

CIK 0001383701operating

Filed

Feb 7, 7:00 PM ET

Accepted

Feb 8, 4:20 PM ET

Size

8.3 KB

Accession

0001209191-16-096375

Insider Transaction Report

Form 4
Period: 2016-02-04
Hagerty David T
EVP, Clinical Development
Transactions
  • Award

    Stock Option (Right to Buy)

    2016-02-04+109,375109,375 total
    Exercise: $1.85Exp: 2026-02-03Common Stock (109,375 underlying)
  • Award

    Stock Option (Right to Buy)

    2016-02-04+21,87521,875 total
    Exercise: $1.85Exp: 2026-02-03Common Stock (21,875 underlying)
Footnotes (2)
  • [F1]The option was granted on February 4, 2016. 25% of the total number of shares of common stock subject to the option will vest on February 4, 2017, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
  • [F2]The Reporting Person was granted a performance based option on February 4, 2016 that will vest, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date, upon the achievement of certain performance conditions, as approved by the Issuer's compensation committee.

Issuer

Conatus Pharmaceuticals Inc.

CIK 0001383701

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001383701

Filing Metadata

Form type
4
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 4:20 PM ET
Size
8.3 KB